PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 29, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

December 1, 2025

Conditions
NSCLC
Interventions
DRUG

PD-1 Antibody

PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1

DEVICE

BACE

Bronchial Arterial Chemoembolization

Trial Locations (8)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Unknown

RECRUITING

People's Hospital of Kaiyang County, Guiyang

RECRUITING

North China University of Science and Technology Affiliated Hospital, Tangshan

RECRUITING

The Second Affiliated Hospital of Xingtai Medical College, Xingtai

RECRUITING

Hebi City Jun County People's Hospital, Hebi

RECRUITING

Wuyang County People's Hospital, Luohe

RECRUITING

Dengzhou People's Hospital, Nanyang

RECRUITING

The Fifth People's Hospital of Puyang City, Puyang

All Listed Sponsors
lead

Xuhua Duan

OTHER